首页 > 最新文献

Revista clinica espanola最新文献

英文 中文
RECALMIN V. Evolution in the activity of internal medicine units of the National Health System (2007-2022).
Pub Date : 2025-02-26 DOI: 10.1016/j.rceng.2025.02.007
J Carretero Gómez, M M Chimeno Viñas, J M Porcel Pérez, M Méndez Bailón, P Pérez Martínez, M T Herranz Marín, N Del Prado, F J Elola Somoza

Objectives: To analyse the structure, activity and results of the Internal Medicine Units (IMUs) of the Spanish National Health System (SNHS). To compare the results of the RECALMIN 2023 survey with previous waves of surveys of the UMIs (2008, 2015, 2017, 2019. 2021) and to analyse trends in the structure, activity and results of the UMIs.

Material and methods: Two data sources: 1) survey on UMI structure and activity; and 2) Hospital discharges of UMIs from the Minimum and Basic Data Set (CMBD) of the SNHS. Cross-sectional descriptive study of the UMIs in acute hospitals of the SNHS with data referring to 2022, comparing them with previous studies.

Results: Over the period 2007-2022, the rate of internists per 100,000 inhabitants increased (IRR: 4.5%; p < 0.001). Inpatient discharges per population and the number of discharges by UMI (IRR: 2.6%; p < 0.005; IRR: 3.5%; p < 0.001, respectively) also increased. The UMIs account for 20% of discharges from general hospitals in the NHS. The SEMI has a database of the CMBD_MIN 2007-2022 with 9,931,401 discharges given by the UMI. The crude in-hospital hospital mortality rate increased in the period 2007-2022 (p < 0.001). From 2020 onwards (SARS-CoV-2 pandemic) overall risk-adjusted and process-adjusted mortality increased (p < 0.001).

Conclusions: UMIs have a central position in SNHS hospital care. The activity of the UMI has grown significantly in the period analysed. The RECALMIN project identifies strengths and opportunities to be strategically addressed by SEMI.

{"title":"RECALMIN V. Evolution in the activity of internal medicine units of the National Health System (2007-2022).","authors":"J Carretero Gómez, M M Chimeno Viñas, J M Porcel Pérez, M Méndez Bailón, P Pérez Martínez, M T Herranz Marín, N Del Prado, F J Elola Somoza","doi":"10.1016/j.rceng.2025.02.007","DOIUrl":"10.1016/j.rceng.2025.02.007","url":null,"abstract":"<p><strong>Objectives: </strong>To analyse the structure, activity and results of the Internal Medicine Units (IMUs) of the Spanish National Health System (SNHS). To compare the results of the RECALMIN 2023 survey with previous waves of surveys of the UMIs (2008, 2015, 2017, 2019. 2021) and to analyse trends in the structure, activity and results of the UMIs.</p><p><strong>Material and methods: </strong>Two data sources: 1) survey on UMI structure and activity; and 2) Hospital discharges of UMIs from the Minimum and Basic Data Set (CMBD) of the SNHS. Cross-sectional descriptive study of the UMIs in acute hospitals of the SNHS with data referring to 2022, comparing them with previous studies.</p><p><strong>Results: </strong>Over the period 2007-2022, the rate of internists per 100,000 inhabitants increased (IRR: 4.5%; p < 0.001). Inpatient discharges per population and the number of discharges by UMI (IRR: 2.6%; p < 0.005; IRR: 3.5%; p < 0.001, respectively) also increased. The UMIs account for 20% of discharges from general hospitals in the NHS. The SEMI has a database of the CMBD_MIN 2007-2022 with 9,931,401 discharges given by the UMI. The crude in-hospital hospital mortality rate increased in the period 2007-2022 (p < 0.001). From 2020 onwards (SARS-CoV-2 pandemic) overall risk-adjusted and process-adjusted mortality increased (p < 0.001).</p><p><strong>Conclusions: </strong>UMIs have a central position in SNHS hospital care. The activity of the UMI has grown significantly in the period analysed. The RECALMIN project identifies strengths and opportunities to be strategically addressed by SEMI.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VERICIDuAT: Real-life study of vericiguat in patients with heart failure with reduced ejection fraction.
Pub Date : 2025-02-20 DOI: 10.1016/j.rceng.2025.02.006
S Russo Botero, M Ripoll Martínez, L Fácila Rubio, A Lamilla Álvarez, V Montagud Balaguer, D García Escrivá, E Chover Sierra, Á Sánchez Montagud, J Pérez Silvestre

Introduction and objectives: The aim of this study is to assess the safety in a real-world cohort of patients with heart failure with reduced ejection fraction (HFrEF).

Methods: Observational, retrospective and single-center study with patients on vericiguat treatment from the Cardiology and Internal Medicine outpatient clinic of the Valencia General University Hospital Consortium during 2023 year and with minimum follow-up of 6 months. Patients with HFpEF diagnosis and optimized treatment according to the ESC 2021 clinical practice guidelines were included, to whom treatment with vericiguat was started.

Results: We included 123 patients with a mean age of 78 years, mostly men (62%) and with NYHA II functional status (52%). 98 patients completed follow-up after a median follow-up of 162 days (IQR 13-343). The average dose of vericiguat used was 8,3 ± 2,7 mg and 75 patients achieved the target dose of 10 mg (71%). At the end of follow-up, no significant changes were observed in the values of proBNP (pg/mL), CA125, hemoglobin (mg/dl), electrolytes, glomerular filtration rate (mL/min/m2) and systolic blood pressure (mmHg). Of all the patients who completed follow-up, 11 (11%) discontinued treatment due to adverse effects, mostly symptomatic hypotension, digestive symptoms and pruritus; 25 died (20%).

Conclusions: The use of vericiguat is safe, if used according to the technical data sheet, in terms of the established parameters. Further long-term studies are needed to evaluate the impact of vericiguat as a potential disease-modifying treatment.

{"title":"VERICIDuAT: Real-life study of vericiguat in patients with heart failure with reduced ejection fraction.","authors":"S Russo Botero, M Ripoll Martínez, L Fácila Rubio, A Lamilla Álvarez, V Montagud Balaguer, D García Escrivá, E Chover Sierra, Á Sánchez Montagud, J Pérez Silvestre","doi":"10.1016/j.rceng.2025.02.006","DOIUrl":"10.1016/j.rceng.2025.02.006","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The aim of this study is to assess the safety in a real-world cohort of patients with heart failure with reduced ejection fraction (HFrEF).</p><p><strong>Methods: </strong>Observational, retrospective and single-center study with patients on vericiguat treatment from the Cardiology and Internal Medicine outpatient clinic of the Valencia General University Hospital Consortium during 2023 year and with minimum follow-up of 6 months. Patients with HFpEF diagnosis and optimized treatment according to the ESC 2021 clinical practice guidelines were included, to whom treatment with vericiguat was started.</p><p><strong>Results: </strong>We included 123 patients with a mean age of 78 years, mostly men (62%) and with NYHA II functional status (52%). 98 patients completed follow-up after a median follow-up of 162 days (IQR 13-343). The average dose of vericiguat used was 8,3 ± 2,7 mg and 75 patients achieved the target dose of 10 mg (71%). At the end of follow-up, no significant changes were observed in the values of proBNP (pg/mL), CA125, hemoglobin (mg/dl), electrolytes, glomerular filtration rate (mL/min/m<sup>2</sup>) and systolic blood pressure (mmHg). Of all the patients who completed follow-up, 11 (11%) discontinued treatment due to adverse effects, mostly symptomatic hypotension, digestive symptoms and pruritus; 25 died (20%).</p><p><strong>Conclusions: </strong>The use of vericiguat is safe, if used according to the technical data sheet, in terms of the established parameters. Further long-term studies are needed to evaluate the impact of vericiguat as a potential disease-modifying treatment.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology.
Pub Date : 2025-02-19 DOI: 10.1016/j.rceng.2025.02.002
S Carrasco-Molina, Á Robles-Marhuenda, J J Ríos-Blanco, Y Tung-Chen

Acute confusional syndrome (ACS) is a disruption of cognitive function and attention that affects up to 42% of hospitalised patients, most commonly in those over the age of 65. It is typically triggered by one or more precipitating factors in predisposed patients. Point-of-care ultrasound (POCUS) emerges as a tool that could be used to provide quick and accurate information in the diagnosis of patients with ACS, potentially reducing the waiting time for critical interventions, decreasing the need for invasive procedures, and possibly improving clinical outcomes. To date, no articles have been published describing the utility of POCUS in patients with ACS. Therefore, this work presents a review of the utility of POCUS in various pathologies that may be related to the development of ACS. Additionally, we propose an action algorithm that integrates clinical evaluation with bedside ultrasound, which could be useful for allowing quick and accurate identification of the underlying causes of ACS and the guidance of appropriate treatment, although prospective studies are needed to confirm this utility.

{"title":"Utility of point-of-care ultrasound (POCUS) in hospitalized patients with acute confusional syndrome of unclear etiology.","authors":"S Carrasco-Molina, Á Robles-Marhuenda, J J Ríos-Blanco, Y Tung-Chen","doi":"10.1016/j.rceng.2025.02.002","DOIUrl":"10.1016/j.rceng.2025.02.002","url":null,"abstract":"<p><p>Acute confusional syndrome (ACS) is a disruption of cognitive function and attention that affects up to 42% of hospitalised patients, most commonly in those over the age of 65. It is typically triggered by one or more precipitating factors in predisposed patients. Point-of-care ultrasound (POCUS) emerges as a tool that could be used to provide quick and accurate information in the diagnosis of patients with ACS, potentially reducing the waiting time for critical interventions, decreasing the need for invasive procedures, and possibly improving clinical outcomes. To date, no articles have been published describing the utility of POCUS in patients with ACS. Therefore, this work presents a review of the utility of POCUS in various pathologies that may be related to the development of ACS. Additionally, we propose an action algorithm that integrates clinical evaluation with bedside ultrasound, which could be useful for allowing quick and accurate identification of the underlying causes of ACS and the guidance of appropriate treatment, although prospective studies are needed to confirm this utility.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Present and future of internists in the Spanish public health system.
Pub Date : 2025-02-19 DOI: 10.1016/j.rceng.2025.02.005
N Ramírez-Perea, D Orozco-Beltrán
{"title":"Present and future of internists in the Spanish public health system.","authors":"N Ramírez-Perea, D Orozco-Beltrán","doi":"10.1016/j.rceng.2025.02.005","DOIUrl":"10.1016/j.rceng.2025.02.005","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Training in clinical ethics, a necessary tool for professional excellence of the internist.
Pub Date : 2025-02-19 DOI: 10.1016/j.rceng.2025.02.003
Carme Font, Paula Martínez de la Cruz, Benjamín Herreros

Internists must respond to increasingly complex clinical scenarios in a context of progressively increasing life expectancy, techno-scientific development and accelerated demographic and sociocultural changes. Ethical reflection is a useful tool to resolve and prevent value conflicts, which are frequent in clinical practice. The ethical training of internists contributes to professional excellence and can be oriented at two complementary levels: 1) development of skills in all internists for the management of "clinical microethics", which allow the integration of the techno-scientific aspects of medicine in a satisfactory clinical relationship at a human level; 2) specialization for internists who are experts in bioethics, to lead ethics committees (and other consulting models) in a more local setting and participate in bioethical debates and the development of normative ethics in a more general setting.

{"title":"Training in clinical ethics, a necessary tool for professional excellence of the internist.","authors":"Carme Font, Paula Martínez de la Cruz, Benjamín Herreros","doi":"10.1016/j.rceng.2025.02.003","DOIUrl":"10.1016/j.rceng.2025.02.003","url":null,"abstract":"<p><p>Internists must respond to increasingly complex clinical scenarios in a context of progressively increasing life expectancy, techno-scientific development and accelerated demographic and sociocultural changes. Ethical reflection is a useful tool to resolve and prevent value conflicts, which are frequent in clinical practice. The ethical training of internists contributes to professional excellence and can be oriented at two complementary levels: 1) development of skills in all internists for the management of \"clinical microethics\", which allow the integration of the techno-scientific aspects of medicine in a satisfactory clinical relationship at a human level; 2) specialization for internists who are experts in bioethics, to lead ethics committees (and other consulting models) in a more local setting and participate in bioethical debates and the development of normative ethics in a more general setting.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complexity based medicine.
Pub Date : 2025-02-19 DOI: 10.1016/j.rceng.2025.02.004
A Ruiz-Cantero
{"title":"Complexity based medicine.","authors":"A Ruiz-Cantero","doi":"10.1016/j.rceng.2025.02.004","DOIUrl":"10.1016/j.rceng.2025.02.004","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A prediction model for complications caused by portal hypertension or liver cancer in a Spanish cohort of chronic hepatitis B patients.
Pub Date : 2025-02-07 DOI: 10.1016/j.rceng.2024.11.009
P Gavilán, J-C Gavilán, E Clavijo, I Viciana, J-A Gonzalez-Correa

Background aims: To identify risk factors associated with liver complications in patients with chronic hepatitis B infection in an unselected cohort of hepatitis B patients in southern Spain.

Methods: A prospective open-cohort study was conducted on 437 patients with uncomplicated chronic hepatitis B infection in two hospitals in Málaga, southern Spain. The follow-up time ranged from 0.5 to 31.5 years (mean: 13.8±9.5 years; median: 11.4 years). The aim of this study was to evaluate the occurrence of the initial liver complication during follow-up, which is defined as the emergence of liver cancer or complications resulting from portal hypertension. Survival curves were obtained using a time-to-event method through Kaplan-Meier analysis. Multivariate Cox regression was conducted to estimate the hazard ratios of risk factors associated with complications after adjusting for multiple variables. The follow-up of the patients was carried out under conditions of usual clinical practice. Based on the weighted adjustment of these factors, we developed a Hepatitis B Complication Score (HBCS) from which it was possible to identify patients with low and high risk of complications during follow-up.

Results: 33 out of 437 patients (7.55%) experienced liver complications, 12 (36.3%) were secondary to portal hypertension, and 21 patients (63.7%) developed liver cancer. A Multivariate Cox regression identified the following independent risk factor: Age above 45 years: HR 7.10 (2.9-17.3); low platelet count: HR 4.88 (2.1-10.9); hepatitis C coinfection: HR 4.68 (2.0-10.9); Male gender: HR 4.64 (1.5-14.2); alkaline phosphatase above 147 UI/mL: HR 4.33 (2.0-8.9); and Child score above 5 points: HR 3.83 (1.7-8.4). The Risk of Complications Score (HBCS) was developed with a high predictive capacity AUROC 0.92 (0.87-0.97).

Conclusion: An HBCS score greater than 3.07 points identifies patients at high risk of developing complications and with an increased risk of liver and all-cause mortality.

{"title":"A prediction model for complications caused by portal hypertension or liver cancer in a Spanish cohort of chronic hepatitis B patients.","authors":"P Gavilán, J-C Gavilán, E Clavijo, I Viciana, J-A Gonzalez-Correa","doi":"10.1016/j.rceng.2024.11.009","DOIUrl":"10.1016/j.rceng.2024.11.009","url":null,"abstract":"<p><strong>Background aims: </strong>To identify risk factors associated with liver complications in patients with chronic hepatitis B infection in an unselected cohort of hepatitis B patients in southern Spain.</p><p><strong>Methods: </strong>A prospective open-cohort study was conducted on 437 patients with uncomplicated chronic hepatitis B infection in two hospitals in Málaga, southern Spain. The follow-up time ranged from 0.5 to 31.5 years (mean: 13.8±9.5 years; median: 11.4 years). The aim of this study was to evaluate the occurrence of the initial liver complication during follow-up, which is defined as the emergence of liver cancer or complications resulting from portal hypertension. Survival curves were obtained using a time-to-event method through Kaplan-Meier analysis. Multivariate Cox regression was conducted to estimate the hazard ratios of risk factors associated with complications after adjusting for multiple variables. The follow-up of the patients was carried out under conditions of usual clinical practice. Based on the weighted adjustment of these factors, we developed a Hepatitis B Complication Score (HBCS) from which it was possible to identify patients with low and high risk of complications during follow-up.</p><p><strong>Results: </strong>33 out of 437 patients (7.55%) experienced liver complications, 12 (36.3%) were secondary to portal hypertension, and 21 patients (63.7%) developed liver cancer. A Multivariate Cox regression identified the following independent risk factor: Age above 45 years: HR 7.10 (2.9-17.3); low platelet count: HR 4.88 (2.1-10.9); hepatitis C coinfection: HR 4.68 (2.0-10.9); Male gender: HR 4.64 (1.5-14.2); alkaline phosphatase above 147 UI/mL: HR 4.33 (2.0-8.9); and Child score above 5 points: HR 3.83 (1.7-8.4). The Risk of Complications Score (HBCS) was developed with a high predictive capacity AUROC 0.92 (0.87-0.97).</p><p><strong>Conclusion: </strong>An HBCS score greater than 3.07 points identifies patients at high risk of developing complications and with an increased risk of liver and all-cause mortality.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Helicobacter pylori infection in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis.
Pub Date : 2025-02-07 DOI: 10.1016/j.rceng.2024.12.004
A González-Saitz, J Díez-Manglano

Objective: To determine the association of HP infection with COPD, assessing its prevalence and influence on symptoms, lung function, quality of life, exacerbations, hospitalizations, mortality, and healthcare costs.

Methods: We performed a systematic review and meta-analysis after conducting a systematic literature search in PubMed, Embase, Cochrane Library, Virtual Health Library, ScienceDirect, Scopus, Researchgate, and GoogleScholar, from database inception to 31/12/2022. We used the Der Simonian-Laird method to calculate pooled HP prevalence, the Mantel-Haenszel model to determine the association of HP with COPD, and the inverse variance method to compare the pulmonary function tests between infected and uninfected patients, always with a fixed-effect model.

Results: Twenty-eight studies included a total of 8647 patients with COPD. The pooled prevalence of HP infection was 29.8% (95%CI 29.0-30.7%). The more severe stage of COPD lesser the prevalence of HP (p < 0.001). HP infection was associated with COPD, estimated odds ratio 1.90 (95%CI 1.71, 2.12), p < 0.001. The mean differences for p%FEV1, p%FVC and FEV1/FVC ratio between HP infected and uninfected patients with COPD were -13.06 (95%CI -14.54, -11.58), -3.72 (95%CI -5.64, -1.79) and -0.01 (95%CI -0.02, -0.00) respectively.

Conclusion: Our meta-analysis suggests an appreciable relationship between HP infection and COPD. Further longitudinal studies considerating confounders and investigating causality are required.

{"title":"Helicobacter pylori infection in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis.","authors":"A González-Saitz, J Díez-Manglano","doi":"10.1016/j.rceng.2024.12.004","DOIUrl":"10.1016/j.rceng.2024.12.004","url":null,"abstract":"<p><strong>Objective: </strong>To determine the association of HP infection with COPD, assessing its prevalence and influence on symptoms, lung function, quality of life, exacerbations, hospitalizations, mortality, and healthcare costs.</p><p><strong>Methods: </strong>We performed a systematic review and meta-analysis after conducting a systematic literature search in PubMed, Embase, Cochrane Library, Virtual Health Library, ScienceDirect, Scopus, Researchgate, and GoogleScholar, from database inception to 31/12/2022. We used the Der Simonian-Laird method to calculate pooled HP prevalence, the Mantel-Haenszel model to determine the association of HP with COPD, and the inverse variance method to compare the pulmonary function tests between infected and uninfected patients, always with a fixed-effect model.</p><p><strong>Results: </strong>Twenty-eight studies included a total of 8647 patients with COPD. The pooled prevalence of HP infection was 29.8% (95%CI 29.0-30.7%). The more severe stage of COPD lesser the prevalence of HP (p < 0.001). HP infection was associated with COPD, estimated odds ratio 1.90 (95%CI 1.71, 2.12), p < 0.001. The mean differences for p%FEV<sub>1</sub>, p%FVC and FEV<sub>1</sub>/FVC ratio between HP infected and uninfected patients with COPD were -13.06 (95%CI -14.54, -11.58), -3.72 (95%CI -5.64, -1.79) and -0.01 (95%CI -0.02, -0.00) respectively.</p><p><strong>Conclusion: </strong>Our meta-analysis suggests an appreciable relationship between HP infection and COPD. Further longitudinal studies considerating confounders and investigating causality are required.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical governance in internal medicine: the challenge of length of stay.
Pub Date : 2025-02-05 DOI: 10.1016/j.rceng.2025.02.001
L S Pinheiro

Clinical governance highlights the relevance of the combination of "quality" and "safety" with "excellence" and "improvement". In hospitals, as highly complex organizations, the principles and practices of clinical governance are key elements for success. Several angles would be pertinent in the application of clinical governance to the hospital context, and specifically to internal medicine. The length of stay of patients in hospital is frequently used as a quality indicator of clinical activity. Ideally the patient should remain in the hospital during the time in which he has benefit, minimizing inherent risks. With its centrality in the patient, clinical governance, interpreted in the light of the Seven Pillars Model, can provide a comprehensive framework for addressing the management of length of stay. We should try to bring to the day-to-day of our organizations the aggregating vision of clinical governance, whose foundational values need to be reinforced and deepened.

{"title":"Clinical governance in internal medicine: the challenge of length of stay.","authors":"L S Pinheiro","doi":"10.1016/j.rceng.2025.02.001","DOIUrl":"10.1016/j.rceng.2025.02.001","url":null,"abstract":"<p><p>Clinical governance highlights the relevance of the combination of \"quality\" and \"safety\" with \"excellence\" and \"improvement\". In hospitals, as highly complex organizations, the principles and practices of clinical governance are key elements for success. Several angles would be pertinent in the application of clinical governance to the hospital context, and specifically to internal medicine. The length of stay of patients in hospital is frequently used as a quality indicator of clinical activity. Ideally the patient should remain in the hospital during the time in which he has benefit, minimizing inherent risks. With its centrality in the patient, clinical governance, interpreted in the light of the Seven Pillars Model, can provide a comprehensive framework for addressing the management of length of stay. We should try to bring to the day-to-day of our organizations the aggregating vision of clinical governance, whose foundational values need to be reinforced and deepened.</p>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential role of lung ultrasonography in outpatient follow-up of patients with COVID-19. A systematic review 肺部超声检查在COVID-19患者门诊随访中的潜在作用。系统回顾。
Pub Date : 2025-02-01 DOI: 10.1016/j.rceng.2024.11.006
F. Navarro-Romero , J. Olalla-Sierra , M.D. Martín-Escalante

Introduction and aim

Currently, the usefulness of lung ultrasound in the follow-up of patients after hospital discharge for SARS-CoV-2 pneumonia is not well known. The main objective of this systematic review is to investigate the persistence of alterations in lung ultrasound of patients who have had COVID-19 pneumonia.

Methods

A systematic review has been carried out following the PRISMA regulations in the PubMed, EMBASE, Web of Science and Google Scholar database from January 2020 to May 2023 using the combination of MeSH terms: “lung ultrasound”, “ultrasonography”, “lung alterations”, “persistence”, “follow-up”, “consequences”, “hospital discharge”, “COVID”, “COVID-19”, “SARS-CoV-2”. Studies were selected that described alterations in the lung ultrasound of patients after having suffered from COVID-19 pneumonia. The JBI Critical Appraisal Tools were used to assess the risk of bias of the studies. No meta-analysis techniques were performed, the results being compared narratively.

Results

From two to six months after COVID-19 pneumonia, pulmonary ultrasound abnormalities appear frequently and are proportional to the intensity of the initial episode. The most frequent anomalies are irregularities in the pleural line, the presence of B lines and/or subpleural consolidations, predominantly in the basal regions of the thorax. These findings seem to correlate with those of the chest CT.

Conclusions

Lung ultrasound offers technical and economic advantages that should be considered for the study of patients after hospital discharge for COVID-19.
简介与目的:目前,肺部超声在SARS-CoV-2肺炎患者出院后随访中的作用尚不清楚。本系统综述的主要目的是调查COVID-19肺炎患者肺部超声改变的持久性。方法:根据2020年1月至2023年5月在PubMed、EMBASE、Web of Science和谷歌Scholar数据库中检索的PRISMA规范,结合MeSH术语:“肺超声”、“超声检查”、“肺改变”、“持续性”、“随访”、“后果”、“出院”、“COVID”、“COVID-19”、“SARS-CoV-2”进行系统综述。我们选择了描述COVID-19肺炎患者肺部超声改变的研究。使用JBI关键评估工具评估研究的偏倚风险。没有进行meta分析技术,结果被叙述比较。结果:新型冠状病毒肺炎后2 ~ 6个月,肺部超声异常频繁出现,且与首发发作强度成正比。最常见的异常是胸膜线不规则,B线和/或胸膜下实变,主要发生在胸基底区。这些发现似乎与胸部CT的结果有关。结论:肺部超声具有技术和经济优势,对COVID-19出院后患者的研究应予以考虑。
{"title":"Potential role of lung ultrasonography in outpatient follow-up of patients with COVID-19. A systematic review","authors":"F. Navarro-Romero ,&nbsp;J. Olalla-Sierra ,&nbsp;M.D. Martín-Escalante","doi":"10.1016/j.rceng.2024.11.006","DOIUrl":"10.1016/j.rceng.2024.11.006","url":null,"abstract":"<div><h3>Introduction and aim</h3><div>Currently, the usefulness of lung ultrasound in the follow-up of patients after hospital discharge for SARS-CoV-2 pneumonia is not well known. The main objective of this systematic review is to investigate the persistence of alterations in lung ultrasound of patients who have had COVID-19 pneumonia.</div></div><div><h3>Methods</h3><div>A systematic review has been carried out following the PRISMA regulations in the PubMed, EMBASE, Web of Science and Google Scholar database from January 2020 to May 2023 using the combination of MeSH terms: “lung ultrasound”, “ultrasonography”, “lung alterations”, “persistence”, “follow-up”, “consequences”, “hospital discharge”, “COVID”, “COVID-19”, “SARS-CoV-2”. Studies were selected that described alterations in the lung ultrasound of patients after having suffered from COVID-19 pneumonia. The JBI Critical Appraisal Tools were used to assess the risk of bias of the studies. No meta-analysis techniques were performed, the results being compared narratively.</div></div><div><h3>Results</h3><div>From two to six months after COVID-19 pneumonia, pulmonary ultrasound abnormalities appear frequently and are proportional to the intensity of the initial episode. The most frequent anomalies are irregularities in the pleural line, the presence of B lines and/or subpleural consolidations, predominantly in the basal regions of the thorax. These findings seem to correlate with those of the chest CT.</div></div><div><h3>Conclusions</h3><div>Lung ultrasound offers technical and economic advantages that should be considered for the study of patients after hospital discharge for COVID-19.</div></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 2","pages":"Pages 101-110"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142756080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista clinica espanola
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1